Table 5 Clinical outcomes in patients with and without active cancer within the asymptomatic VTE patients
From: Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
Asymptomatic PE with/without DVT | Asymptomatic DVT | |||||||
|---|---|---|---|---|---|---|---|---|
Total | With active cancer | Without active cancer | P-value | Total | With active cancer | Without active cancer | P-value | |
n = 197 | n = 54 | n = 143 | n = 203 | n = 55 | n = 148 | |||
Recurrence or aggravation of symptomatic VTE | 6 (3.0%) | 1 (1.9%) | 5 (3.5%) | 1.00 | 6 (3.0%) | 1 (1.8%) | 5 (3.4%) | 1.00 |
Recurrence or aggravation of symptomatic PE | 3 (1.5%) | 1 (1.9%) | 2 (1.4%) | 1.00 | 1 (0.5%) | 0 (0.0%) | 1 (0.7%) | 1.00 |
Recurrence or aggravation of symptomatic DVT | 4 (2.0%) | 0 (0.0%) | 4 (2.8%) | 0.58 | 5 (2.5%) | 1 (1.8%) | 4 (2.7%) | 1.00 |
Acute coronary syndrome | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | - | 1 (0.5%) | 0 (0.0%) | 1 (0.7%) | 1.00 |
Ischemic stroke | 4 (2.0%) | 2 (3.7%) | 2 (1.4%) | 0.30 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | - |
Death from any cause | 17 (8.6%) | 14 (25.9%) | 3 (2.1%) | < 0.001 | 23 (11.3%) | 16 (29.1%) | 7 (4.7%) | < 0.001 |
Death related to VTE | 2 (1.0%) | 1 (1.9%) | 1 (0.7%) | 0.47 | 1 (0.5%) | 0 (0.0%) | 1 (0.7%) | 1.00 |
Death related to CVD | 3 (1.5%) | 1 (1.9%) | 2 (1.4%) | 1.00 | 1 (0.5%) | 0 (0.0%) | 1 (0.7%) | 1.00 |
Major bleeding | 4 (2.0%) | 0 (0.0%) | 4 (2.8%) | 0.58 | 6 (3.0%) | 4 (7.3%) | 2 (1.4%) | 0.047 |
Minor bleeding | 7 (3.6%) | 3 (5.6%) | 4 (2.8%) | 0.40 | 14 (6.9%) | 3 (5.5%) | 11 (7.4%) | 0.76 |
Fatal bleeding | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | - | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | - |
Clinically relevant events | 25 (12.7%) | 14 (25.9%) | 11 (7.7%) | 0.001 | 33 (16.3%) | 18 (32.7%) | 15 (10.1%) | < 0.001 |